Karin von Wachenfeldt

CEO and cofounder of Truly Labs AB and Truly Translational Sweden AB. Ph. D. In Immunotechnology from Lund University and Marketing Economist (EFL). Broad experience of early stage pharmaceutical development of small molecules and biopharmaceuticals from BioInvent, Pharmacia Upjohn, Active Biotech and AstraZeneca.